Cellebrite and Chainalysis partner to modernize digital
PETAH TIKVA, Israel and TYSONS CORNER, Virginia and NEW YORK, 05 July. 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in digital intelligence (DI) solutions for the public and private sectors, and Chainalysis, the blockchain data platform, have launched a partnership to enable customers to easily identify and assess criminal activities involving cryptocurrency in digital investigations to expedite their resolution.
The use of cryptocurrency has increased dramatically over the past few years. Although the vast majority of its use is for legitimate purposes, it has also been exploited for illicit purposes through scams, money laundering, ransomware, and more. As cryptocurrency artifacts are more frequently found and can be used as key pieces of digital evidence, law enforcement and businesses need access to cryptocurrency-related knowledge and tools to investigate criminal activities and help solve cases.
Together, Cellebrite and Chainalysis enable clients to modernize investigations by leveraging the transparency of blockchains. The integrated solution will provide automated and efficient capabilities and insights to identify and assess cryptocurrency risks and correlate this information with additional elements of a related case. Cellebrite’s suite of DI solutions will reveal accurate, real-time cryptocurrency data and insights from Chainalysis’ data platform. Through this cooperation, examiners, investigators, analysts and compliance officers will be able to seamlessly identify illicit cryptocurrency-related activity in one place as part of their investigation workflows. Familiar digital survey.
Cellebrite and Chainalysis are also collaborating to enable clients to bridge the cryptocurrency knowledge gap. Together, they will train clients’ in-house experts by providing cryptocurrency training and providing expert cryptocurrency investigation services, as well as making Chainalysis’ Reactor, the investigation tool, available for advanced cryptocurrency tracing.
“Cryptocurrency, like any other financial instrument, has become a means of financing crime and money laundering, and as its adoption increases, our customers must be equipped with state-of-the-art solutions to identify this important category. digital evidence”, said Leeor Ben-Peretz, Chief Strategy Officer at Cellebrite. “Providing our clients with an integrated cryptocurrency investigation solution will accelerate their investigations through automation and help them seamlessly uncover a wider range of digital evidence within the suite of digital intelligence solutions. of Cellebrite. We are pleased to partner with Chainalysis to further enhance our clients’ tools and insights, modernize investigations and speed up justice.
“We are delighted to partner with Cellebrite, the market leader in digital intelligence, to expand our public and private sector customer base and provide them with access to Chainalysis solutions, training and expertise,” said Thomas Stanley, President and Chief Revenue Officer at Chainalysis. . “Together, Cellebrite and Chainalysis are committed to helping fight blockchain crime, improving trust and transparency in blockchains, and making cryptocurrency safer for everyone.”
The initial integrated solution is expected to be available in Q3 2022. To learn more about the partnership offerings, please visit: https://cellebrite.com/en/cellebrite-crypto-solution-powered-by-chainalysis/
Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, expedite justice and uphold privacy in communities around the world. We are a global leader in digital intelligence solutions for the public and private sectors, enabling organizations to master the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and enterprises worldwide, Cellebrite’s digital intelligence platform and solutions are transforming the way clients collect, review, analyze and manage survey data sanctioned by law. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.
Chainalysis is the blockchain data platform. We provide data, software, services and research to government agencies, stock exchanges, financial institutions and insurance and cybersecurity companies in more than 70 countries. Our data powers investigative, compliance and market intelligence software that has been used to solve some of the world’s most high-profile criminal cases and expand consumer access to cryptocurrency safely. Backed by Accel, Addition, Benchmark, Coatue, GIC, Paradigm, Ribbit and other leading venture capital firms, Chainalysis builds trust in blockchains to promote more financial freedom with less risk. For more information, visit www.chainalysis.com.
Caution Regarding Forward-Looking Statements
This document contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “forecast”, ” intention, “Seek”, “target”, “anticipate”, “will”, “appear”, “approximate”, “plan”, “could”, “possible”, “potential”, “believe”, “could”, “predict”, “should”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and others similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information. Such forward-looking statements regarding revenues, earnings, performance, strategies, prospects and other aspects of the ac Cellebrite’s performance are based on current expectations which are subject to risks and uncertainties. A number of factors could cause actual results or results to differ materially from those indicated by these forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with ever-changing technological advances and industry standards; Cellebrite’s material dependence on acceptance of its solutions by law enforcement and government agencies; Actual or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s inability to maintain the productivity of sales and marketing personnel, including with respect to hiring, onboarding and retention of personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; inadvertent or deliberate misuse of Cellebrite solutions; political and reputational factors relating to Cellebrite’s business or operations; risks relating to market opportunity estimates and market growth forecasts; Cellebrite’s ability to successfully manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third party suppliers for certain components, products or services; challenges associated with large transactions and the long sales cycle; risks that Cellebrite’s customers will not meet their contractual or payment obligations; risks associated with a significant portion of Cellebrite’s business from government customers around the world; risks relating to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyberattacks, breaches, failures or disruptions of computer systems; mishandling or perceived mishandling of sensitive or confidential information; complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; the risks associated with different corporate governance requirements applicable to Israeli companies and the risks associated with being a foreign private issuer and an emerging growth company; market volatility in Cellebrite’s stock price; change tax laws and regulations; risks associated with joint ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, business compliance, anti-money laundering and economic sanctions laws and regulations; risks relating to the suitability of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section entitled “Risk Factors” of Cellebrite’s Annual Report on Form 20-F filed with the SEC on March 29, 2022 and in other documents filed by Cellebrite with the United States Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, if circumstances change, except as required by applicable securities and other laws. .
VP Investor Relations
+972 73 394 8440
On-chain analysis media
Senior Director of Communications